Company PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.27 ^USD	+0.31%		+23.63%	-34.21%

Mar. 28	B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating	MT
Mar. 27	Empire Metals targets key milestones in Australia	AN

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.

Number of employees: 25

Managers	Title	Age	Since
Frank Bedu-Addo FOU	Founder	59	19-03-14
Lars Robert Boesgaard DFI	Director of Finance/CFO	55	Dec. 03
David Schaaf CTO	Chief Tech/Sci/R&D Officer	-	22-08-31
Spencer Brown CMP	Compliance Officer	54	22-05-31
Gregory Conn CTO	Chief Tech/Sci/R&D Officer	69	04-12-31
Joe J. Dervan CTO	Chief Tech/Sci/R&D Officer	-	-

Members of the board	Title	Age	Since
Stephen Glover CHM	Chairman	65	19-04-01
Otis Brawley BRD	Director/Board Member	64	20-11-02
Richard Sykes BRD	Director/Board Member	79	19-02-28
Kamil Ali-Jackson BRD	Director/Board Member	65	20-02-20
Gregory Freitag BRD	Director/Board Member	62	19-02-28
Frank Bedu-Addo FOU	Founder	59	19-03-14
Ilian Iliev BRD	Director/Board Member	48	20-04-07

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,679,275	35,333,177 ( 96.33 %)	0	96.33 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 5.817 %	1,809,454	5.817 %	7 M $
Vanguard Fiduciary Trust Co. 4.840 %	1,505,671	4.840 %	6 M $
Frank Bedu-Addo 2.221 %	690,866	2.221 %	3 M $
Geode Capital Management LLC 2.036 %	633,204	2.036 %	3 M $
STATE STREET CORPORATION 1.775 %	552,032	1.775 %	2 M $
Richard Sykes 1.431 %	445,108	1.431 %	2 M $
Jefferies Financial Services, Inc. 1.286 %	400,000	1.286 %	2 M $
Tang Capital Management LLC 1.286 %	400,000	1.286 %	2 M $
Inspirion Wealth Advisors LLC 1.141 %	354,977	1.141 %	1 M $
Susquehanna Securities LLC 0.8397 %	261,218	0.8397 %	1 M $

PDS Biotechnology Corp.

303A College Road East

08540, Princeton

http://www.pdsbiotech.com

address PDS Biotechnology Corporation(PDSB)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.27 USD

Average target price

14.4 USD

Spread / Average Target

+340.37%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PDS BIOTECHNOLOGY CORPORATION	-34.21%	120M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs